Shots:
- The company has introduced Uzpruvo, biosimilar of Stelara (ustekinumab) across the EU to treat gastroenterology, dermatology & rheumatology indications. Uzpruvo is available in a pre-filled syringes with a thinner needle & is latex-free to avoid allergic reactions
- Further EU launches are expected in the upcoming mos., pending national price approvals through a fully European supply chain
- Uzpruvo was approved across the EU in Jan 2024 to treat adults with Crohn’s disease & psoriatic arthritis plus plaque psoriasis in adults & children (from 6yrs.)
Ref: STADA and Alvotech | Image: STADA and Alvotech| Press Release
Related News:- Samsung Bioepis Reports the US FDA’s Approval of Epysqli (Biosimilar, Soliris)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
